Fig. 2: Radiological and pathological outcomes of participants. | Nature Communications

Fig. 2: Radiological and pathological outcomes of participants.

From: Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study

Fig. 2: Radiological and pathological outcomes of participants.The alternative text for this image may have been generated using AI.

a Waterfall plots of radiological regression of target lesions for patients after neoadjuvant Afatinib treatment (n = 46). b Evaluation the relationship between the duration of neoadjuvant Afatinib therapy and pathological regression of patients after surgery (n = 33). Source data are provided as a Source Data file. LN: lymph node; MPR: major pathologic response; NAT: neoadjuvant Afatinib treatment; PD: progressive disease; PR: partial response; R0 Resection: complete resection; R1/2 Resection: uncomplete resection; SD: stable disease; VATS: video-assisted thoracic surgery.

Back to article page